Andrew W. Hahn, MD, presented “Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Hahn, Andrew W. “Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/choosing-systemic-therapy-for-men-with-metastatic-hormone-sensitive-prostate-cancer/
Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer – Summary
Andrew W. Hahn, MD, analyzes systemic therapy choices for men with metastatic hormone-sensitive prostate cancer. His presentation delves into the critical factors influencing treatment decisions and the latest advancements in therapeutic options.
Dr. Hahn begins by outlining current systemic therapies, including androgen deprivation therapy (ADT) and its combination with other agents. By discussing the mechanisms of action and the efficacy of various therapeutic agents, Dr. Hahn provides a detailed examination of the available treatment options.
Dr. Hahn also addresses the role of personalized medicine in managing metastatic hormone-sensitive prostate cancer. He highlights the importance of genetic profiling and biomarker testing in tailoring treatment plans to individual patients.
Throughout the presentation, Dr. Hahn underscores the dynamic nature of prostate cancer treatment, with ongoing research continually informing and refining clinical practice.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Dr. Andrew Hahn is an Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center. Andrew earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee. Dr. Hahn completed Internal Medicine residency and a Chief Medicine Resident year at the University of Utah followed by his Medical Oncology fellowship at MD Anderson Cancer Center. His clinical focus is on prostate and kidney cancers. His research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. Dr. Hahn has published over 40 peer-reviewed original research articles and authored or co-authored 30 other editorials, reviews, and book chapters. His work has been supported by an ASCO Conquer Cancer Foundation Young Investigator Award, Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award.
